ClinicalTrials.gg
Active, not recruitingNCT06449859Updated Jun 10, 2024

A Clinical Trial of TQC2938 Injection in Healthy Adult Subjects

A Phase 1 interventional study of TQC2938 Injection and TQC2938 Placebo in Asthma, sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-10.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Nov 2024, 2 years ago, but the record still lists the study as active, not recruiting.
  • Registered 11 months after the study started (first participant enrolled Jun 2023, registered Jun 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 251 studies in Asthma with a site in China — 87 open to participants now, 96 under way, 15 of them phase 3. Asthma · China.

Planned enrollment
128th of 182
84 · median 203
Started
2023
with 22 others
Phase 1
31 of 251
3 open now
Primary completion
2024-11
later than 7 of 95 live
Registered
166th of 251
by date

Among the 251 studies in Asthma with a site in China, this one is the 128th largest by planned enrollment of the 182 interventional ones that give a count, is one of 23 that started in 2023, is one of 31 in phase 1, reaches primary completion later than 7 of the 95 other live ones, and was the 166th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

87 of the 251 studies in Asthma with a site in China are open now. Recruiting first, the newest first:

82 more — sign in →

All 87 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 251 studies in Asthma with a site in China, or all of them as a file.
02

Study summary

The study is designed in two phases: single-dose administration and multiple-dose administration. A randomized, double-blind, placebo-controlled trial design was used to evaluate the safety, tolerability, pharmacokinetic characteristics and immunogenicity of TQC2938 injection in healthy adults.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sign before the study to fully understand the purpose, process and possible adverse reactions of the test.
  • Adults aged between 18 and 60 years (inclusive),both male and female;
  • The male subject should weigh at least 50kg, the female subject should weigh at least 45kg. And (BMI) within 18\~28 kg/m2 (inclusive);
  • The subjects were able to communicate well with the investigators, voluntarily and were able to understand and follow the protocol to complete the study;
  • Female patient had no plans to become pregnant for 6 months from the date of signing the informed consent to the last dose, and must use effective non-drug with their sexual partners of childbearing age。

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women;
  • Past medical history or current cardiac, endocrine, metabolic, renal, hepatic, gastrointestinal, skin, infection, hematological, neurological or psychiatric diseases/abnormalities, or related chronic abnormalities, or related chronic diseases, or acute diseases, and the investigator evaluated that the subject was not suitable for the trial;
  • People who have abnormal and results in vital signs, physical examination, laboratory tests, 12-lead (ECG) and Chest radiograph during screening period;
  • Subjects Positive for Any of Virus Surface Antigen (HBsAg), Virus Antibody (Anti-HCV), Antibody (Anti-HIV), and Treponema Pallidum Antibody (Anti-TP);
  • A history of clinically significant infections, including upper respiratory tract infections (URTI) and lower respiratory tract infections (LRTI), occurred within 30 days prior to and during screening and required antibiotic or antiviral treatment;
  • Had undergone surgery within 8 weeks prior to screening period or expected to undergo surgery during the study period;
  • Participated in any clinical trial within 3 months prior to the screening period;
  • Received immunoglobulins or blood products within 30 days prior to randomization;
  • Blood donation or significant blood loss of more than 400 mL within 3 months prior to randomization, or plan to donate blood within 3 months;
  • Potential blood collection difficulties, can not tolerate venipuncture or have a history of fainting needles and fainting blood;
  • A history of allergic reaction to treatment with another therapeutic monoclonal antibody or biologics, a history of any well-defined drug or food allergy, especially to ingredients similar to the drug in this trial;
  • Those who received or planned to receive inactivated or active vaccines within 30 days prior to randomization or throughout the study period, including the follow-up period;
  • Those who smoked more than 5 cigarettes/day or used a comparable amount of nicotine or nicotine-containing products in the 6 months prior to randomization, or could not stop using any tobacco products during the trial period;
  • People with chronic alcohol abuse or who drank more than 14 units of alcohol per week in the 3 months prior to screening (1 unit =360 mL beer or 45 mL spirits with 40% alcohol or 150 mL wine), or who could not abstain during the test period, or who tested positive for alcohol breath;
  • History of drug abuse or a positive result of urine drug test at screening;
  • Received any marketed or biological agent (other than vaccines) within 4 months or 5 half-lives (whichever is older) prior to randomization;
  • Any prescription, over-the-counter, and herbal medicines, except vitamin products, were taken in the 4 weeks prior to randomization;
  • Use of any systemic cytotoxicity or systemic within 6 months prior to randomization or during the study period, or any local cytotoxin or local immunosuppressive drug within 30 days or 5 half-life periods (whichever is longer) prior to randomization or during the study period;
  • Any situation in which the investigator believes that this poses a safety risk to the subject in the trial or may interfere with the conduct of the study, or that the investigator believes that the subject may not be able to complete the study or may not be able to comply with the requirements of the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    TQC2938 Injection (52.5mg/0.35ml)

    TQC2938 Injection is administered as a single dose of subcutaneous (SC) injection.

    Drug: TQC2938 Injection

  • Experimental
    TQC2938 Injection (210mg/1.4ml)-subcutaneous injection

    TQC2938 Injection is administered as a single dose of subcutaneous injection.

    Drug: TQC2938 Injection

  • Experimental
    TQC2938 Injection (210mg/1.4ml)-intravenous injection

    TQC2938 Injection is administered as a single dose of intravenous (IV) injection .

    Drug: TQC2938 Injection

  • Experimental
    TQC2938 Injection (420mg/2.8ml)

    TQC2938 Injection is administered as a single dose of subcutaneous injection.

    Drug: TQC2938 Injection

  • Experimental
    TQC2938 Injection (840mg/5.6ml)-subcutaneous injection

    TQC2938 Injection is administered as a single dose of subcutaneous injection.

    Drug: TQC2938 Injection

  • Experimental
    TQC2938 Injection (1260mg/8.4ml)

    TQC2938 Injection is administered as a single dose of subcutaneous injection.

    Drug: TQC2938 Injection

  • Experimental
    TQC2938 Injection (210mg/1.4ml)-subcutaneous injection-multiple doses

    TQC2938 Injection is administered as a multiple doses of subcutaneous injection, once every 28 days, three times in total.

    Drug: TQC2938 Injection

  • Experimental
    TQC2938 Injection (840mg/5.6ml)-subcutaneous injection-multiple doses

    TQC2938 Injection is administered as a multiple doses of subcutaneous injection, once every 28 days, three times in total.

    Drug: TQC2938 Injection

  • Experimental
    TQC2938 Injection (630mg/4.2ml)

    TQC2938 Injection is administered as a multiple doses of subcutaneous injection, once every 28 days, three times in total.

    Drug: TQC2938 Injection

  • Placebo comparator
    TQC2938 Placebo

    TQC2938 Placebo is administered as a single dose or multiple doses, once every 28 days, three times in total.

    Drug: TQC2938 Placebo

Interventions

  • TQC2938 injection is a humanized monoclonal antibody that interfering with the signal cascade.

  • DrugTQC2938 Placebo

    TQC2938 Placebo is a placebo comparator

06

What researchers measure

Primary outcomes

  1. Adverse events (AEs)

    The occurrence of all adverse events (AEs).

    Time frame: Single dose: Up to Day 113. Multiple doses: Up to Day 169

  2. Serious adverse events (SAEs)

    The occurrence and incidence of all serious adverse events (SAEs).

    Time frame: Single dose: Up to Day 113. Multiple doses: Up to Day 169

  3. Clinical laboratory abnormalities

    Incidence of abnormal clinical laboratory examination, vital signs, physical examination, 12-lead electrocardiogram, etc.

    Time frame: Single dose: Up to Day 113. Multiple doses: Up to Day 169

Secondary outcomes

  1. Maximum serum concentration (Cmax) of subcutaneous injection for single dose

    The Cmax is the maximum observed serum concentration of study drug.

    Time frame: Single dose: pre-dose (-1 to 0 hour),1, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 264, 336, 504, 672, 1008, 1344, 1680, 2016, 2352 and 2688 hours post-dose

  2. Maximum serum concentration (Cmax) of intravenous injection for single dose

    The Cmax is the maximum observed serum concentration of study drug.

    Time frame: Single dose: pre-dose (-1 to 0 hour), 0.5hours after the start of administration, and 0,0.25, 0.5, 1, 2, 4, 8, 24, 48, 72, 96, 120, 144, 168, 192, 264, 336, 504, 672, 1008, 1344, 1680, 2016, 2352, 2688 hours post-dose

  3. Maximum serum concentration (Cmax) of subcutaneous injection for multiple doses

    The Cmax is the maximum observed serum concentration of study drug.

    Time frame: Multiple doses: pre-dose (-1 to 0 hour) of days 1, 29, 57, and 1, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 264, 336, 504 hours post-dose on multiple dose of days 1 and 57, and 672, 1008, 1344, 1680, 2016, 2352, 2688 hours post-dose of day 57

  4. Time to reach maximum observed serum concentration (Tmax) of subcutaneous injection for single dose

    Time to reach maximum (peak) serum concentration following drug administration.

    Time frame: Single dose: pre-dose (-1 to 0 hour),1, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 264, 336, 504, 672, 1008, 1344, 1680, 2016, 2352 and 2688 hours post-dose

  5. Time to reach maximum observed serum concentration (Tmax) of intravenous injection for single dose

    Time to reach maximum (peak) serum concentration following drug administration.

    Time frame: Single dose: pre-dose (-1 to 0hour), 0.5hours after the start of administration, and 0,0.25, 0.5, 1, 2, 4, 8, 24, 48, 72, 96, 120, 144, 168, 192, 264, 336, 504, 672, 1008, 1344, 1680, 2016, 2352, 2688 hours post-dose

  6. Time to reach maximum observed serum concentration (Tmax) of subcutaneous injection for multiple doses

    Time to reach maximum (peak) serum concentration following drug administration.

    Time frame: Multiple doses: pre-dose (-1 to 0hour) of days 1, 29, 57, and 1, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 264, 336, 504hours post-dose of days 1 and 57, and 672, 1008, 1344, 1680, 2016, 2352, 2688 hours post-dose of day 57

  7. Minimum concentration of drug in serum at steady state (Cmin, ss) of subcutaneous injection for multiple doses

    Cmin,ss is the minimum serum concentration at steady state.

    Time frame: Multiple doses: Pre-dose (-1 to 0 hour) of day 1, day 29, day 57, and 1, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 264, 336, 504 hours of day 1 and day 57, and 672, 1008, 1344, 1680, 2016, 2352, 2688 hours post-dose of day 57

  8. Area under the concentration-time curve from 0 to last observation (AUC [0-t]) of subcutaneous injection for single dose

    Area under the concentration-time curve of the TQC2938 Injection in serum over the time interval from 0 extrapolated to the last quantifiable data point.

    Time frame: Single dose: pre-dose (-1 to 0 hour),1, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 264, 336, 504, 672, 1008, 1344, 1680, 2016, 2352 and 2688 hours post-dose

  9. Area under the concentration-time curve from 0 to last observation (AUC [0-t]) of intravenous injection for single dose

    Area under the concentration-time curve of the TQC2938 Injection in serum over the time interval from 0 extrapolated to the last quantifiable data point.

    Time frame: Single dose: pre-dose (-1 to 0 hour), 0.5 hours after the start of administration, and 0,0.25, 0.5, 1, 2, 4, 8, 24, 48, 72, 96, 120, 144, 168, 192, 264, 336, 504, 672, 1008, 1344, 1680, 2016, 2352, 2688 hours post-dose

  10. Area under the concentration-time curve from 0 to last observation (AUC [0-t]) of of subcutaneous injection for multiple dose

    Area under the concentration-time curve of the TQC2938 Injection in serum over the time interval from 0 extrapolated to the last quantifiable data point.

    Time frame: Multiple doses: pre-dose(-1 to 0 hour) of day 1, day 29, day 57, and 1, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 264, 336, 504 hours post-dose of day 1 and day 57, and 672, 1008, 1344, 1680, 2016, 2352, 2688 hours post-dose of day 57

  11. Maximum concentration of drug in serum at steady state (Cmax, ss) of subcutaneous injection for multiple doses

    Cmax, ss is the peak serum concentration of TQC2938 Injection during dosing interval at steady state.

    Time frame: Multiple doses: pre-dose (-1 to 0 hour) of day 1, day 29, day 57, and 1, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 264, 336, 504 hours post-dose of day 1 and day 57, and 672, 1008, 1344, 1680, 2016, 2352, 2688 hours post-dose of day 57

  12. Time to maximum serum concentration at steady state (Tmax, ss) of subcutaneous injection

    Tmax,ss is defined as time to reach the peak serum concentration at steady state for TQC2938 Injection.

    Time frame: Multiple doses: pre-dose (-1 to 0 hour) of day 1, day 29, day 57, and 1, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 264, 336, 504 hours post-dose of day 1 and day 57, and 672, 1008, 1344, 1680, 2016, 2352, 2688 hours post-dose of day 57

  13. Area under curve of steady state (AUCss) of subcutaneous injection

    To evaluate the pharmacokinetics (PK) of multiple ascending doses (MAD) of TQC2938 Injection in serum.

    Time frame: Multiple doses: pre-dose (-1 to 0 hour) of day 1, day 29, day 57, and 1, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 264, 336, 504 hours post-dose of day 1 and day 57, and 672, 1008, 1344, 1680, 2016, 2352, 2688 hours post-dose of day 57

  14. Half-life (t1/2) of subcutaneous injection for single dose

    Terminal phase elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the serum.

    Time frame: Single dose: pre-dose (-1 to 0 hour),1, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 264, 336, 504, 672, 1008, 1344, 1680, 2016, 2352 and 2688 hours post-dose

  15. Half-life (t1/2) of intravenous injection for single dose

    Terminal phase elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the serum.

    Time frame: Single dose: pre-dose (-1 to 0 hour), 0.5 hours after the start of administration, and 0,0.25, 0.5, 1, 2, 4, 8, 24, 48, 72, 96, 120, 144, 168, 192, 264, 336, 504, 672, 1008, 1344, 1680, 2016, 2352, 2688 hours post-dose

  16. Half-life (t1/2) of intravenous injection for multiple dose

    Terminal phase elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the serum.

    Time frame: Multiple doses: pre-dose (-1 to 0 hour) of day 1, day 29, day 57, and 1, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 264, 336, 504 hours post-dose of day 1 and day 57, and 672, 1008, 1344, 1680, 2016, 2352, 2688 hours post-dose of day 57

  17. Apparent volume of distribution (Vd/F) of subcutaneous injection for single dose

    Apparent volume of distribution of the TQC2938 Injection in serum.

    Time frame: Single dose: pre-dose (-1 to 0 hour),1, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 264, 336, 504, 672, 1008, 1344, 1680, 2016, 2352 and 2688 hours post-dose

  18. Apparent volume of distribution (Vd/F) of intravenous injection for single dose

    Apparent volume of distribution of the TQC2938 Injection in serum.

    Time frame: Single dose: pre-dose (-1 to 0 hour), 0.5 hours after the start of administration, and 0,0.25, 0.5, 1, 2, 4, 8, 24, 48, 72, 96, 120, 144, 168, 192, 264, 336, 504, 672, 1008, 1344, 1680, 2016, 2352, 2688 hours post-dose

  19. Apparent volume of distribution (Vd/F) of subcutaneous injection for multiple dose

    Apparent volume of distribution of the TQC2938 Injection in serum.

    Time frame: Multiple doses: pre-dose (-1 to 0 hour) of day 1, day 29, day 57, and 1, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 264, 336, 504 hours post-dose of day 1 and day 57, and 672, 1008, 1344, 1680, 2016, 2352, 2688 hours post-dose of day 57

  20. Apparent clearance (CL/F) of subcutaneous injection for single dose

    Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the body.

    Time frame: Single dose: pre-dose (-1 to 0 hour),1, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 264, 336, 504, 672, 1008, 1344, 1680, 2016, 2352 and 2688 hours post-dose

  21. Apparent clearance (CL/F) of intravenous injection for single dose

    Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the body.

    Time frame: Single dose: pre-dose (-1 to 0 hour), 0.5 hours after the start of administration, and 0,0.25, 0.5, 1, 2, 4, 8, 24, 48, 72, 96, 120, 144, 168, 192, 264, 336, 504, 672, 1008, 1344, 1680, 2016, 2352, 2688 hours post-dose

  22. Apparent clearance (CL/F) of subcutaneous injection for multiple dose

    Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the body.

    Time frame: Multiple doses: pre-dose (-1 to 0 hour) of day 1, day 29, day 57, and 1, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 264, 336, 504 hours post-dose of day 1 and day 57, and 672, 1008, 1344, 1680, 2016, 2352, 2688 hours post-dose of day 57

  23. Accumulation ratio (Rac) of subcutaneous injection for multiple dose

    To evaluate the pharmacokinetics (PK) of multiple ascending doses (MAD) of TQC2938 Injection in serum.

    Time frame: Multiple doses: pre-dose (-1 to 0 hour) of day 1, day 29, day 57, and 1, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 264, 336, 504 hours post-dose of day 1 and day 57, and 672, 1008, 1344, 1680, 2016, 2352, 2688 hours post-dose of day 57

  24. Anti-drug antibodies (ADA)

    Incidence of ADA, a participant was considered ADA-positive across the study if they had a positive reading at any time point during the study.

    Time frame: Single dose: (-1 to 0 hour) (pre-dose), 672, 1344, 2016 and 2688 hours postdose. Multiple doses: (-1 to 0 hour) before the first,second and third administration, 1344 and 2688 hours after intravenous injection of Day 57

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Nov 2024, 17 months after the start.

Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's planned 17 months is above that.

Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2024
First posted
Jun 10, 2024
StartActual
Jun 13, 2023
Primary completionEst.
Nov 2024
CompletionEst.
Nov 2024
Last update
Jun 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06449859
Responsible party
Sponsor
First posted
Jun 10, 2024
Start date
Jun 13, 2023
Primary completion
Nov 2024 (estimated)
Completion
Nov 2024 (estimated)
Last update
Jun 10, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TQC2938

Start the discussion